Immunotherapeutic uses of CpG oligodeoxynucleotides (original) (raw)

• Marrack, P. & Kappler, J. Subversion of the immune system by pathogens. Cell 76, 323–332 (1994).
  Article CAS PubMed Google Scholar
• Medzhitov, R. & Janeway, C. A. Innate immunity, impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4–9 (1997).
  Article CAS PubMed Google Scholar
• Medzhitov, R. & Janeway, C. A. Innate immunity, the virtues of a nonclonal system of recognition. Cell 91, 295–298 (1998).
  Article Google Scholar
• Paul, W. E. (ed.) in Fundamental Immunology 1–20 (Raven Press, New York, 2003).
  Google Scholar
• Underhill, D. M. & Ozinsky, A. Toll-like receptors, key mediators of microbe detection. Curr. Opin. Immunol. 14, 103–110 (2002).
  Article CAS PubMed Google Scholar
• Vasselon, T. & Detmers, P. A. Toll receptors, a central element in innate immune responses. Infect. Immun. 70, 1033–1041 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Razin, A. & Friedman, J. DNA methylation and its possible biological roles. Prog. Nucl. Acid Res. 25, 33–52 (1981).
  Article CAS Google Scholar
• Cardon, L. R., Burge, C., Clayton, D. A. & Karlin, S. Pervasive CpG suppression in animal mitochondrial genomes. Proc. Natl Acad. Sci. USA 91, 3799–3803 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000). This paper shows that Toll-like receptor 9 (TLR9) mediates CpG recognition in mice.
  Article CAS PubMed Google Scholar
• Takeshita, F. et al. Cutting Edge, role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167, 3555–3558 (2001). The authors show that TLR9 mediates CpG recognition in humans, and that CpG DNA co-localizes with TLR9 in endosomal vesicles.
  Article CAS PubMed Google Scholar
• Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98, 9237–9242 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Wagner, H. Bacterial CpG-DNA activates immune cells to signal 'infectious danger'. Adv. Immunol. 73, 329–368 (1999).
  Article CAS PubMed Google Scholar
• Yamamoto, S. et al. Antitumor effect of nucleic acid fraction from bacteria. Proc. Jpn. Soc. Immunol. 48, 272–281 (1989).
  Google Scholar
• Yamamoto, S. et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148, 4072–4076 (1992).
  CAS PubMed Google Scholar
• Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–548 (1995). This work was the first to identify unmethylated CpG motifs as crucial mediators of immune activation. Studies showed that B cells responded to CpG motifs by proliferating and secreting immunoglobulin.
  Article CAS PubMed Google Scholar
• Klinman, D. M., Yi, A., Beaucage, S. L., Conover, J. & Krieg, A. M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNγ. Proc. Natl Acad. Sci. USA 93, 2879–2883 (1996). The first work to establish that unmethylated CpG motifs elicited a complex immunomodulatory cascade that included the production of T helper 1 (T H 1)-type and pro-inflammatory cytokines.
  Article CAS PubMed PubMed Central Google Scholar
• Jahrsdorfer, B. & Weiner, G. J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Investig. Drugs 4, 686–690 (2003).
  PubMed Google Scholar
• Carpentier, A. F., Auf, G. & Delattre, J. Y. CpG-oligonucleotides for cancer immunotherapy, review of the literature and potential applications in malignant glioma. Front Biosci. 8, 115–127 (2003).
  Article Google Scholar
• Ishii, K. J. et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196, 269–274 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Yi, A. K. et al. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160, 4755–4761 (1998).
  CAS PubMed Google Scholar
• Hacker, H. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230–6540 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Takeshita, F., Ishii, K. J., Ueda, A., Ishigatsubo, Y. & Klinman, D. M. Positive and negative regulatory elements contribute to CpG oligonucleotide-mediated regulation of human IL-6 gene expression. Eur. J. Immunol. 30, 108–116 (2000).
  Article CAS PubMed Google Scholar
• Yamamoto, M. et al. Cutting edge, a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169, 6668–6672 (2002).
  Article CAS PubMed Google Scholar
• Takeshita, F. & Klinman, D. M. CpG ODN-mediated regulation of IL-12 p40 transcription. Eur. J. Immunol. 30, 1967–1976 (2000).
  Article CAS PubMed Google Scholar
• Hacker, H. et al. Immune cell activation by bacterial CpG-DNA through myeroid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 192, 595–600 (2000). This paper describes much of the intracellular signalling cascade that is triggered by the interaction of CpG DNA with TLR9.
  Article CAS PubMed PubMed Central Google Scholar
• Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782–787 (2000).
  Article CAS PubMed Google Scholar
• Ishii, K. J. et al. CpG-activated plasmacytoid dendritic cells protect against lethal Listeria monocytogenes infection. J. Immunol. (in the press).
• Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J. & Klinman, D. M. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides. J. Leuk. Biol. 71, 813–820 (2002).
  CAS Google Scholar
• Hornung, V. et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531–4537 (2002).
  Article CAS PubMed Google Scholar
• Sun, S., Zhang, X., Tough, D. F. & Sprent, J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188, 2335–2342 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Stacey, K. J., Sweet, M. J. & Hume, D. A. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157, 2116–2120 (1996).
  CAS PubMed Google Scholar
• Ballas, Z. D., Rasmussen, W. L. & Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157, 1840–1847 (1996).
  CAS PubMed Google Scholar
• Roman, M. et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nature Med. 3, 849–854 (1997).
  Article CAS PubMed Google Scholar
• Halpern, M. D., Kurlander, R. J. & Pisetsky, D. S. Bacterial DNA induces murine interferon-γ production by stimulation of IL-12 and tumor necrosis factor-α. Cell Immunol. 167, 72–78 (1996).
  Article CAS PubMed Google Scholar
• Rankin, R. et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucl. Acid Drug Dev. 11, 333–340 (2001).
  Article CAS Google Scholar
• Verthelyi, D., Ishii, K. J., Gursel, M., Takeshita, F. & Klinman, D. M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol. 166, 2372–2377 (2001). This is the first work to demonstrate that distinct types of CpG oligodeoxynucleotide (ODN) exist, and that human immune cells are differentially responsive to these different ODNs.
  Article CAS PubMed Google Scholar
• Krug, A. et al. Identification of CpG oligonucleotide sequences with high induction of IFNα/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31, 2154–2163 (2001).
  Article CAS PubMed Google Scholar
• Kadowaki, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863–869 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Krug, A. et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026–3037 (2001).
  Article CAS PubMed Google Scholar
• Bauer, M. et al. Bacterial CpG DNA triggers activation and maturation of human CD11c−, CD123+ dendritic cells. J Immunol. 166, 5000–5007 (2001).
  Article CAS PubMed Google Scholar
• Hartmann, G. et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-α induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633–1641 (2003).
  Article CAS PubMed Google Scholar
• Marshall, J. D. et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73, 781–792 (2003).
  Article CAS PubMed Google Scholar
• Hartmann, G. & Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944–952 (2000).
  Article CAS PubMed Google Scholar
• Verthelyi, D. et al. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168, 1659–1663 (2002).
  Article CAS PubMed Google Scholar
• Davis, H. L. et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18, 1920–1924 (2000).
  Article CAS PubMed Google Scholar
• Verthelyi, D. & Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109, 64–71 (2003).
  Article CAS PubMed Google Scholar
• Broide, D. H. et al. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of TH2 responses in a mouse model of asthma. J. Clin. Immunol. 21, 175–182 (2001).
  Article CAS PubMed Google Scholar
• Kanellos, T. S. et al. Mammalian granulocyte–macrophage colony stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish. Immunology 96, 507–510 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Gomis, S. et al. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun. 71, 857–863 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Pyles, R. B. et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J. Virol. 76, 11387–11396 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ashkar, A. A., Bauer, S., Mitchell, W. J., Vieira, J. & Rosenthal, K. L. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77, 8948–8956 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Klinman, D. M., Conover, J. & Coban, C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect. Immun. 67, 5658–5663 (1999).
  CAS PubMed PubMed Central Google Scholar
• Krieg, A. M., Homan, L. L., Yi, A. K. & Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161, 2428–2434 (1998).
  CAS PubMed Google Scholar
• Walker, P. S. et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ dependent mechanisms. Proc. Natl Acad. Sci. USA 96, 6970–6975 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Elkins, K. L., Rhinehart-Jones, T. R., Stibitz, S., Conover, J. S. & Klinman, D. M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162, 2291–2298 (1999).
  CAS PubMed Google Scholar
• Zimmermann, S. et al. CpG oligodeoxynucleotides trigger protective and curative TH1 responses in lethal murine Leishmaniasis. J. Immunol. 160, 3627–3630 (1998). This work was the first to establish that CpG ODNs could be used to increase host resistance to infectious pathogens.
  CAS PubMed Google Scholar
• Klinman, D. M. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucl. Acid Drug Dev. 8, 181–184 (1998).
  Article CAS Google Scholar
• Chiaramonte, M. G., Hesse, M., Cheever, A. W. & Wynn, T. A. CpG Oligonucleotides can prophylactically immunize against TH2-mediated schistosome egg induced pathology by an IL-12 independent mechanism. J. Immunol. 164, 973–985 (2000).
  Article CAS PubMed Google Scholar
• Yamamoto, T., Yamamoto, S., Katoaka, T. & Tokunaga, T. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances IFN production and natural killer activity. Microbiol. Immunol. 38, 831–836 (1994).
  Article CAS PubMed Google Scholar
• Klinman, D. M., Barnhart, K. M. & Conover, J. CpG motifs as immune adjuvants. Vaccine 17, 19–25 (1999).
  Article CAS PubMed Google Scholar
• Pacanowski, J. et al. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98, 3016–3021 (2001).
  Article CAS PubMed Google Scholar
• Azzoni, L. et al. Sustained impairment of IFNγ secretion in suppressed HIV-infected patients despite mature NK cell recovery, evidence for a defective reconstitution of innate immunity. J. Immunol. 168, 5764–5770 (2002).
  Article CAS PubMed Google Scholar
• Chehimi, J. et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168, 4796–4801 (2002).
  Article CAS PubMed Google Scholar
• Corbett, E. L. et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 359, 2177–2187 (2002).
  Article PubMed Google Scholar
• Verthelyi, D. et al. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J. Immunol. 170, 4717–4723 (2003).
  Article CAS PubMed Google Scholar
• Weinberg, E. D. Pregnancy-associated depression of cell-mediated immunity. Rev. Infect. Dis. 6, 814–831 (1984).
  Article CAS PubMed Google Scholar
• Priddy, K. D. Immunologic adaptations during pregnancy. J. Obstet. Gynecol. Neonatal Nurs. 26, 388–394 (1997).
  Article CAS PubMed Google Scholar
• Wegmann, T. G., Lin, H., Guilbert, L. & Mosmann, T. R. Bidirectional cytokine interactions in the maternal–fetal relationship, is successful pregnancy a TH2 phenomenon? Immunol. Today 14, 353–356 (1993).
  Article CAS PubMed Google Scholar
• Lin, H., Mosmann, T. R., Guilbert, L., Tuntipopipat, S. & Wegmann, T. G. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J. Immunol. 151, 4562–4573 (1993).
  CAS PubMed Google Scholar
• Raghupathy, R. TH1-type immunity is incompatible with successful pregnancy. Immunol. Today 18, 478–482 (1997).
  Article CAS PubMed Google Scholar
• Sano, M., Mitsuyama, M., Watanabe, Y. & Nomoto, K. Impairment of T cell-mediated immunity to Listeria monocytogenes in pregnant mice. Microbiol. Immunol. 30, 165–176 (1986).
  Article CAS PubMed Google Scholar
• Krishnan, L. et al. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-γ response and increased production of T helper 2 cytokines. J. Immunol. 156, 644–652 (1996).
  CAS PubMed Google Scholar
• Ito, S., Ishii, K., Shirot, H. & Klinman, D. M. CpG oligodeoxynucleotides improve the survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect. Immunol. (in the press).
• Amaral, V. F. et al. Leishmania amazonensis: the asian rhesus macaques (Macaca mulata) as an experimental model for the study of cutaneous leishmaniasis. Exp. Parasitol. 82, 34–44 (1996).
  Article CAS PubMed Google Scholar
• Equils, O. et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells, implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170, 5159–5164 (2003).
  Article CAS PubMed Google Scholar
• Olbrich, A. R., Schimmer, S. & Dittmer, U. Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J. Virol. 77, 10658–10662 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Gursel, I., Gursel, M., Ishii, K. J. & Klinman, D. M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167, 3324–3328 (2001).
  Article CAS PubMed Google Scholar
• Davis, H. L. et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870–876 (1998).
  CAS PubMed Google Scholar
• Shirota, H. et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 167, 66–74 (2001).
  Article CAS PubMed Google Scholar
• Moldoveanu, Z., Love-Homan, L., Huang, W. Q. & Krieg, A. M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1216–1224 (1998).
• Kovarik, J. et al. CpG oligonucleotides can cirmcuvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming. J. Immunol. 162, 1611–1617 (1999).
  CAS PubMed Google Scholar
• McCluskie, M. J. & Davis, H. L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161, 4463–4466 (1998).
  CAS PubMed Google Scholar
• Brazolot Millan, C. L., Weeratna, R., Krieg, A. M., Siegrist, C. A. & Davis, H. L. CpG DNA can induce strong TH1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl Acad. Sci. USA 95, 15553–15558 (1998).
  Article CAS PubMed Google Scholar
• Eastcott, J. W. et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19, 1636–1642 (2001).
  Article CAS PubMed Google Scholar
• Branda, R. F. et al. Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J. Lab. Clin. Med. 128, 329–338 (1996).
  Article CAS PubMed Google Scholar
• Horner, A. A. et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell. Immunol. 190, 77–82 (1998).
  Article CAS PubMed Google Scholar
• McCluskie, M. J. & Davis, H. L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19, 413–422 (2000).
  Article CAS PubMed Google Scholar
• Jones, T. R. et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine 17, 3065–3071 (1999). This report demonstrates that CpG ODNs designed for human use could act as immune adjuvants in non-human primates.
  Article CAS PubMed Google Scholar
• Klinman, D. M., Xie, H., Little, S. F., Currie, D. & Ivins, B. CpG Oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine (in the press).
• von Stebut, E. et al. Leishmania major infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis. Eur. J. Immunol. 30, 3498–3506 (2000).
  Article CAS PubMed Google Scholar
• Prince, G. A. et al. Immunoprotective activity and safety of a respiratory syncytial virus vaccine, mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 77, 13156–13160 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Davis, H. L. Use of CpG DNA for enhancing specific immune responses. Curr. Top. Microbiol. Immunol. 247, 171–184 (2000).
  CAS PubMed Google Scholar
• Sears, M. R. Worldwide trends in asthma mortality. Bull. Int. Union Tuberc. Lung Dis. 66, 79–83 (1991).
  CAS PubMed Google Scholar
• Nakajima, H. et al. CD4+ T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. Am. Rev. Respir. Dis. 146, 374–377 (1992).
  Article CAS PubMed Google Scholar
• Robinson, D. S. et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326, 298–304 (1992).
  Article CAS PubMed Google Scholar
• Nakajima, H., Iwamoto, I. & Yoshida, S. Aerosolized recombinant interferon-γ prevents antigen-induced eosinophil recruitment in mouse trachea. Am. Rev. Respir. Dis. 148, 1102–1104 (1993).
  Article CAS PubMed Google Scholar
• Sur, S. et al. Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J. Immunol. 157, 4173–4180 (1996).
  CAS PubMed Google Scholar
• Shirakawa, T., Enomoto, T., Shimazu, S. & Hopkin, J. M. The inverse association between tuberculin responses and atopic disorder. Science 275, 77–79 (1997).
  Article CAS PubMed Google Scholar
• Erb, K. J., Holloway, J. W., Sobeck, A., Mol, l H. & Le Gros, G. Infection of mice with _Mycobacterium bovis_-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J. Exp. Med. 187, 561–569 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Sur, S. et al. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162, 6284–6291 (1999).
  CAS PubMed Google Scholar
• Kline, J. N. et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555–2559 (1998). This work was the first to establish that the combination of CpG ODNs plus allergen had a beneficial effect on allergic asthma.
  CAS PubMed Google Scholar
• Santeliz, J. V., Van Nest, G., Traquina, P., Larsen, E. & Wills-Karp, M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109, 455–462 (2002).
  Article CAS PubMed Google Scholar
• Horner, A. A. et al. Immunostimulatory DNA inhibits IL-4-dependent IgE synthesis by human B cells. J. Allergy Clin. Immunol. 108, 417–423 (2001).
  Article CAS PubMed Google Scholar
• Coyle, A. J. et al. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production, inhibition by a non-anaphylactogenic anti-IgE antibody. J. Exp. Med. 183, 1303–1310 (1996).
  Article CAS PubMed Google Scholar
• Snapper, C. M., Peschel, C. & Paul, W. E. Interferon-γ stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J. Immunol. 140, 2121–2130 (1988).
  CAS PubMed Google Scholar
• Tighe, H. et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 30, 1939–1947 (2000).
  Article CAS PubMed Google Scholar
• Tighe, H. et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106, 124–134 (2000).
  Article CAS PubMed Google Scholar
• Horner, A. A. et al. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J. Allergy Clin. Immunol. 106, 349–356 (2000).
  Article CAS PubMed Google Scholar
• Horner, A. A., Takabaysahi, K., Zubeldia, J. M. & Raz, E. Immunostimulatory DNA-based therapeutics for experimental and clinical allergy. Allergy 57 (Suppl. 72), 24–29 (2002).
  Article PubMed Google Scholar
• Horner, A. A. et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J. Allergy Clin. Immunol. 110, 413–420 (2002).
  Article CAS PubMed Google Scholar
• Horner, A. A. & Raz, E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation, two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 110, 706–712 (2002).
  Article CAS PubMed Google Scholar
• Gilkeson, G. S., Riuz, P., Howell, D., Lefkowith, J. B. & Pisetsky, D. S. Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. Clin. Immunol. Immunopathol. 68, 283–292 (1993).
  Article CAS PubMed Google Scholar
• Gilkeson, G. S., Pippen, A. M. & Pisetsky, D. S. Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J. Clin. Invest. 95, 1398–1402 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Steinberg, A. D., Krieg, A. M., Gourley, M. F. & Klinman, D. M. Theoretical and experimental approaches to generalized autoimmunity. Immunol. Rev. 118, 129–163 (1990).
  Article CAS PubMed Google Scholar
• Klinman, D. M. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J. Clin. Invest. 86, 1249–1254 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Linker-Israeli, M. et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J. Immunol. 147, 117–123 (1991).
  CAS PubMed Google Scholar
• Krieg, A. M. CpG DNA, a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol. 15, 284–292 (1995).
  Article CAS PubMed Google Scholar
• Yi, A. -K., Hornbeck, P., Lafrenz, D. E. & Krieg, A. M. CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-Myc and Bcl-xl. J. Immunol. 157, 4918–4925 (1996).
  CAS PubMed Google Scholar
• Mor, G. et al. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 8, 293–300 (1997).
  Article CAS PubMed Google Scholar
• Katsumi, A. et al. Humoral and cellural immunity to an encoded protein induced by direct DNA injection. Hum. Gene Ther. 5, 1335–1339 (1994).
  Article CAS PubMed Google Scholar
• Gilkeson, G. S. et al. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J. Immunol. 161, 3890–3895 (1998).
  CAS PubMed Google Scholar
• Segal, B. M., Klinman, D. M. & Shevach, E. M. Microbial products induce autoimmune disease by an IL-12 dependent process. J. Immunol. 158, 5087–5091 (1997).
  CAS PubMed Google Scholar
• Segal, B. M., Chang, J. T. & Shevach, E. M. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalotogenic T cells in vivo. J. Immunol. 164, 5683–5688 (2000).
  Article CAS PubMed Google Scholar
• Bachmaier, K. et al. Chlamydia infections and heart disease linked through antigenic mimicry. Science 283, 1335–1339 (1999).
  Article CAS PubMed Google Scholar
• Zeuner, R. A., Verthelyi, D., Gursel, M., Ishii, K. J. & Klinman, D. M. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 48, 1701–1707 (2003).
  Article CAS PubMed Google Scholar
• Sparwasser, T. et al. Bacterial DNA causes septic shock. Nature 386, 336–338 (1997).
  Article CAS PubMed Google Scholar
• Cowdery, J. S., Chace, J. H., Yi, A. -K. & Krieg, A. M. Bacterial DNA induces NK cells to produce IFNγ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156, 4570–4575 (1996).
  CAS PubMed Google Scholar
• Hartmann, G., Krug, A., Waller, K. & Endres, S. Oligodeoxynucleotides enhance LPS-stimulated synthesis of TNF, dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2, 429–438 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Heikenwalder, M. et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nature Med. 10, 187–192 (2004).
  Article CAS PubMed Google Scholar
• Klinman, D. M. et al. DNA vaccines, safety and efficacy issues. Springer Semin. Immunopathol. 19, 245–256 (1997).
  Article CAS PubMed Google Scholar
• Wang, R. et al. Induction of antigen specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476–480 (1998).
  Article CAS PubMed Google Scholar
• Calarota, S. et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Lancet 351, 1320–1325 (1998).
  Article CAS PubMed Google Scholar
• Yacyshyn, B. R. et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment. Pharmacol. Ther. 16, 1761–1770 (2002).
  Article CAS PubMed Google Scholar
• Liu, M. A. DNA vaccines, a review. J. Intern. Med. 253, 402–410 (2003).
  Article CAS PubMed Google Scholar
• Halperin, S. A. et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461–2467 (2003).
  Article CAS PubMed Google Scholar
• Klinman, D. M. et al. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 13, 289–296 (2000).
  CAS PubMed Google Scholar
• Klinman, D. M. CpG DNA as a vaccine adjuvant. Expert Rev. Vacc. 2, 305–315 (2003).
  Article CAS Google Scholar
• Magone, M. T., Chan, C. C., Beck, L., Whitcup, S. M. & Raz, E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol. 30, 1841–1850 (2000).
  Article CAS PubMed Google Scholar
• von Hunolstein, C. et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine 19, 3058–3066 (2001).
  Article CAS PubMed Google Scholar
• Temperton, N. J. et al. Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine, adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. J. Med. Virol. 70, 86–90 (2003).
  Article CAS PubMed Google Scholar
• Al Mariri, A. et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect. Immun. 69, 4816–4822 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hogarth, P. J., Jahans, K. J., Hecker, R., Hewinson, R. G. & Chambers, M. A. Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine 21, 977–982 (2003).
  Article CAS PubMed Google Scholar
• Su, Z., Tam, M. F., Jankovic, D. & Stevenson, M. M. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect. Immun. 71, 5178–5187 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mendez, S. et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect. Immun. 71, 5121–5129 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Frank, F. M. et al. Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine 22, 77–86 (2003).
  Article CAS PubMed Google Scholar